Cargando…
Emerging role of glucocorticoid receptor in castration resistant prostate cancer: A potential therapeutic target
Glucocorticoids are used as co-medication with chemotherapy for solid tumors to reduce inflammation as well as cytotoxic side effects and are effective in easing symptoms related to chemotherapy. However, emerging evidence suggests that glucocorticoids may contribute to failure of chemotherapy and t...
Autor principal: | Kumar, Raj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959034/ https://www.ncbi.nlm.nih.gov/pubmed/31942193 http://dx.doi.org/10.7150/jca.32497 |
Ejemplares similares
-
Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022) -
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2017) -
Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014) -
Castration-resistant prostate cancer: potential targets and therapies
por: Parray, Aijaz, et al.
Publicado: (2012) -
Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012)